AGA Family of Websites: Gastro.org
Search

My GEJ cancer patient can’t tolerate treatment: What’s next?

Explore emerging antibody conjugates in this on-demand series.
gastroesophageal reflux disease (GERD)
gastroesophageal reflux disease (GERD)

Health care professionals are often stymied in how to treat patients with gastric or gastroesophageal junction (GEJ) cancers who become resistant to first-line therapy or who cannot tolerate treatment due to toxicities. Fortunately, emerging antibody conjugates that target HER2 have shown activity against such tumors.

Join an expert panel of clinicians from Memorial Sloan Kettering Cancer Center and the University of Leuven for an on-demand series exploring HER2 testing, care options, Trastuzumab resistance, and side effect management. Complete the pre-session questionnaire to customize your learning experience across four modules.

Expanding treatment options with ADCs in HER2-positive gastric or gastroesophageal junction adenocarcinoma

Module 1: Impact of HER2 testing and implications for prognosis

Module 2: Defining care for HER2+ gastric or GEJ cancer

Module 3: Moving beyond Trastuzumab resistance and unresectability

Module 4: Managing unique adverse events

Expanding treatment options with ADCs in HER2-positive gastric or gastroesophageal junction adenocarcinoma

Module 1: Impact of HER2 testing and implications for prognosis

Module 2: Defining care for HER2+ gastric or GEJ cancer

Module 3: Moving beyond Trastuzumab resistance and unresectability

Module 4: Managing unique adverse events

AGA clinical guidance

Find the latest evidence-based recommendations for treating your patients.

X